Immunotherapy drug pembrolizumab shows early promise for mesothelioma patients

19 abril 2015

The PD-1 inhibitor pembrolizumab, a cancer immunotherapy drug, shrank or halted growth of tumors in 76 percent of patients with pleural mesothelioma, a rare and deadly form of cancer that arises in the outer lining of the lungs and internal chest wall, according to a new study. Patients diagnosed with the disease, which is tied to exposure to asbestos, have a median survival rate of about one year.
http://feeds.sciencedaily.com/~r/sciencedaily/~3/YONKnbYCucM/150419193721.htm

Volver